Patent Landscape for US Patent 10,125,102 (Claim Scope, Coverage, and Filing-By-Family Implications)
US Patent 10,125,102 is drafted as a broad Markush-claim chemical patent (Formula II, with dependent narrowing via specific X/Y/R groups) paired with composition and plasma kallikrein inhibition treatment method claims. The core enforcement risk for generics, biosimilar-like competitors (if any relevant analogs exist), and follow-on chemistry sits in the breadth of the Formula II Markush scope plus the method claim tethered to unwanted plasma kallikrein activity, which can cover multiple indications via the same pharmacological mechanism.
The claim set you provided indicates the patent is not limited to one binding mode, one salt, one dosing route, or one single disease label. It instead covers: (i) large classes of substituted compounds meeting Formula II constraints, (ii) “pharmaceutically acceptable salt” forms, (iii) pharmaceutical compositions, and (iv) therapeutic methods for a wide list of plasma-kallikrein mediated conditions, with explicit “angioedema” and “hereditary angioedema” as end-point anchor indications.
What patents protect the chemical scope of US 10,125,102 Formula II compounds?
Direct answer: US 10,125,102 protects compounds of Formula II (including pharmaceutically acceptable salts) through a dense Markush framework, with dependent claims specifying additional narrowing (X/Y/R4, R3-aryl constraints, and R4=cyclopropyl examples).
How broad is Formula II’s Markush backbone?
Claim 1 (Formula II) makes X the primary structural switch and gives X an expansive list of substituent types spanning:
- simple carbonyl and heteroatom-bearing groups (C(OH), C(O(C1-C6)alkyl), C(O)N, C(O), etc.)
- amine and azide-like/heteroatom functional groups (—C(NH2), —C(NRaRb), —C(N3))
- cyano and nitro (—C(CN), —C(NO2))
- sulfonyl/sulfinyl and sulfur variants (—C(S(O)nRa), —C(SO2...) variants, —C[S(O)(ORc)] etc.)
- ring-fused carbonyl and sulfonamide-like linkages (—C[—C(═O)Rc] and related amide/sulfone motifs)
- halogen and alkyl/carbocycle/arene substituent options (—C(halogen), —C[(C1-C5)alkyl], —C[(C4-C8)carbocyclyl], —C[aryl(C1-C8)alkyl], etc.)
- additional heteroatom/functional handles (P(O), —O—, S(O)N, S(O)2N, etc.)
This is a classic strategy: the scaffold is controlled by the formula’s variables (X, Y, Z, R1c, R2, R3, R3a, R4, and substituent constraints Rc/Rd/Ra/Rb), but X alone allows many chemical “exit vectors” that can map to multiple medicinal chemistry series.
What is the role of Y and R4 in claim 1?
The claim uses conditional statements tied to X. For many X values, it requires “if X represents , then —Y—R4 is present,” while for X = C(O) or —O— it makes Y/R4 absent.
When present, Y—R4 is itself a Markush enumerating multiple substituent classes:
- alkyl-substituted linking motifs (—((C1-C6)alkyl)-R4)
- carbonyl-linked and amino-linked variants (—CH2C(O)—R4, —CH2NH—R4, —NHC(O)—R4, etc.)
- heterocycle and OR4 forms (heterocyclyl-R4, —OR4, —OCH2-R4)
- thioether-like and sulfidic forms (—SCH2R4, —SR4)
This produces broad coverage of terminal functional group conversions (amide/amine/ether/thioether-like) so long as the defined Y—R4 relationship is satisfied.
What is Z and how does it bound aromatic/heteroaromatic substitution?
Z is “absent or represents one or more substituents” selected from a long list (halo, hydroxy, alkyl, CF3, alkoxy, aryl/aryloxy, amino, amino-alkyl, cyano, carbonyl/amido/sulfonamide like substituents, cycloalkyl, and more).
There is also an alternative where Z is a 5- or 6-membered aromatic heterocycle containing 1 to 4 heteroatoms selected from N/O/S.
So the patent isn’t just protecting a single aryl substituent. It can cover heteroaryl substitution patterns.
How are R1c, R2, R3, R3a, and R4 constrained?
- R1c: a broad set of substituent types including halo, amino(C1-C6)alkyl, alkoxy, cyano, guanidine-like (C(═NH)NH2), amide-like (CONRaRb), SO2CH3, formyl, acyl, NH2, and carboxylate/derivative forms with alkyl/haloalkyl esters.
- R2: halo, alkyl, cycloalkyl, fluoroalkyl, OCH3, Si(CH3)3, CONH2, carboxylic acid, cyano, phenyl.
- R3: when present, optionally substituted aryl/heteroaryl/phenyl/carbocyclyl/heterocyclyl or (in claim 3) “phenylene-R3a.”
- R3a: substituent set or alternatively a heteroaryl ring (5- or 6-membered with 1-4 heteroatoms).
- R4: hydrogen, hydroxy, substituted alkyl/cycloalkyl, heterocyclyl(C1-C6)alkyl, aryl/heteroaryl(C1-C6)alkyl, —CH2OH, —CH((C1-C6)alkyl)OH, amino, cyano, plus a specific fused-ring option:
- “—(CRaRb)r(CRaRb)p— fused to the 4-position of the ring bearing Z” to form a 5- to 7-membered heterocycle.
R4 also has a “position fusion” element, which is often used to protect ring-closed analogs that might otherwise escape by only varying substituents.
Dependent claim examples indicate targeted coverage
Your dependent claims give three specific narrowing handles:
- Claim 2: X = CH and both Y and R4 are present.
- Claim 3: R3 is phenylene-R3a, which forces R3 into a benzene-bridge topology.
- Claim 7: R4 is cyclopropyl, a clear “point-of-claim” example that can be used for stronger infringement narratives against actual commercial or lead compounds.
- Claims 8–9: a second formula class (Formula III) with a reduced set of X options, still covering Y—R4 and Z, and again pointing out R4 = cyclopropyl.
What formulations and delivery formats are protected by the pharmaceutical composition claim?
Direct answer: Claim 12 protects a pharmaceutical composition containing a compound of claim 1 plus a pharmaceutically acceptable carrier.
What does that imply for infringement strategy?
The claim language is broad and does not limit:
- dosage form (tablet, capsule, injection, inhalation, etc.)
- route of administration
- excipients
- sustained-release vs immediate release
- salt selection
So if an accused product contains an infringing compound (or a salt falling under “pharmaceutically acceptable salt”), the carrier/dosage-form defenses become less relevant at claim scope level.
What methods of use are claimed for plasma kallikrein activity in US 10,125,102?
Direct answer: Claims 13–16 protect methods for treating unwanted plasma kallikrein activity, with explicit indication coverage including a long list and specific anchors for angioedema and hereditary angioedema.
How broad is the indication list?
Claim 14 lists conditions including:
- stroke
- inflammation
- reperfusion injury
- acute myocardial infarction
- deep vein thrombosis
- post fibrinolytic treatment condition
- angina
- edema
- angioedema
- hereditary angioedema
- sepsis
- arthritis
- hemorrhage
- blood loss during cardiopulmonary bypass
- inflammatory bowel disease
- diabetes mellitus and multiple diabetic complications (retinopathy, diabetic macular edema, diabetic macular degeneration)
- age-related macular edema/macular degeneration
- proliferative retinopathy
- neuropathy
- hypertension
- brain edema
- increased albumin excretion and macroalbuminuria
- nephropathy
Claim 15 narrows to angioedema; claim 16 narrows to hereditary angioedema.
What legal leverage does “mechanism-tethered use” provide?
A mechanism tether (“characterized by unwanted plasma kallikrein activity”) can support enforcement when:
- the accused product’s pharmacology is consistent with kallikrein inhibition, and
- the treated condition can be framed as having that unwanted activity.
This can be advantageous for method-of-use infringement even if the marketing indication is narrower, depending on evidence of indication practice and the patent’s claim interpretation in litigation.
Which dependent claims narrow coverage most effectively for claim charting?
Direct answer: Claims 2, 3, 7, 9, and the Formula III dependent narrowing (8–9) are the clearest “map points” for building infringement claim charts.
Most chartable narrowing
- R4 = cyclopropyl (Claim 7 and Claim 9)
This is a rare but strong specificity feature. It allows a cleaner comparison if the accused compound has cyclopropyl at the relevant position.
- X = CH with required Y/R4 (Claim 2)
This narrows the allowed substitution pattern for the X variable and ties presence/absence to structural features.
- R3 = phenylene-R3a (Claim 3)
This constrains topology, useful when identifying whether an accused compound uses a phenylene bridge.
How does Formula III scope compare with Formula II (X options and Z/R constraints)?
Direct answer: Formula III (claim 8 onward) is narrower on its face for X and Z, but still preserves broad Markush coverage through Y—R4, R1c/R2/R3a/R4, and the fused heterocycle option.
X constraint reduction in Formula III
In claim 8, X options are limited to:
- CH, C(OH), C(O(C1-C6)alkyl), C(O)N, CH2N, N, C(O), or —O—
This is fewer than Formula II’s expanded X list.
Z alternatives appear reduced
In claim 8, Z is absent or represents halo/hydroxy/alkyl/CF3/OCF3/alkoxy/aryl/aryloxy/amino/aminoalkyl/C(O)NH2/cyano/SO2(C1-C6)alkyl/SO2NH2 or (C3-C8)cycloalkyl.
The heterocycle option for Z appears missing from claim 8’s excerpt compared with claim 1’s explicit heterocycle alternative.
Bottom line
Formula II is broader in X and includes Z heterocycle options more explicitly. Formula III still captures large chemical space and still includes the “cyclopropyl R4” dependent claim path.
What generic entry risks exist if a competitor is developing a plasma kallikrein inhibitor?
Direct answer: The patent’s biggest generic-risk vectors are (i) compound identity falling within Formula II/III Markush coverage and (ii) method claims aligned with kallikrein-mediated indications.
Compound-scope risk (chemical Markush)
If a generic developer uses medicinal chemistry to generate an analog that still satisfies:
- the X/Y/R4 conditional presence requirements,
- Z substituent option(s),
- R1c/R2/R3/R3a/R4 restrictions,
then the compound may still be within claim 1’s coverage even if it is not an exact match to a specific example.
Markush patents create infringement risk even for “near neighbors,” because the claim is defined by variable sets rather than a single structure.
Method-of-use risk (mechanism tether)
If a competitor’s label or real-world use is directed to angioedema/hereditary angioedema or other plasma kallikrein-mediated conditions, the method claims provide a pathway to liability depending on infringement proof standards used in the relevant forum.
How strong is the patent estate for US 10,125,102 based only on the provided claims?
Direct answer: Based strictly on claim scope as drafted, strength is driven by:
- wide chemical coverage (multiple variables with broad sets),
- broad composition coverage (carrier only),
- broad method-of-use coverage across a wide condition list tied to plasma kallikrein activity,
- explicit narrowing exemplars (cyclopropyl R4, X=CH, phenylene-R3a).
This combination increases the probability that an accused compound or product regimen can be argued to fall within the claim language.
Key Takeaways
- US 10,125,102 claim 1 is a high-coverage Markush claim covering Formula II compounds (and salts) with extensive allowed values for X, Z, R1c, R2, R3, R3a, and R4, including conditional rules on whether Y—R4 must be present or absent based on X.
- Dependent claims provide structured narrowing points: X=CH with Y and R4 present (Claim 2), phenylene-R3a topology (Claim 3), and a particularly useful specific example R4 = cyclopropyl (Claim 7).
- Formula III (Claims 8–9) narrows X options relative to Formula II but keeps meaningful breadth through other variables and still includes R4 = cyclopropyl.
- Claim 12 broadly covers pharmaceutical compositions containing the claimed compound with a pharmaceutically acceptable carrier.
- Claims 13–16 protect treatment methods for conditions characterized by unwanted plasma kallikrein activity, with extensive indication coverage and explicit anchors in angioedema and hereditary angioedema.
FAQs
1) What makes Markush “X/Y/R4” conditional language important for infringement?
Conditional presence/absence requirements let a patentee argue that variants fail or succeed based on whether the claimed substitution pattern is satisfied exactly for the relevant X category.
2) Does Claim 12 require a specific dosage form or route?
No. Claim 12 requires only a pharmaceutical composition with a pharmaceutically acceptable carrier.
3) Can a competitor avoid infringement by changing indications while using the same drug?
Method claims tie liability to treating conditions characterized by unwanted plasma kallikrein activity; avoidance depends on factual and legal standards for method-of-use infringement.
4) Which single dependent claim is most useful for building a short claim chart?
The dependent claim specifying R4 = cyclopropyl (Claim 7, mirrored in Claim 9 for Formula III).
5) Is Formula III completely separate from Formula II or an additional coverage track?
It is an additional coverage track with reduced X and Z options in the excerpt, but it preserves the same overall structural logic with Y—R4 and fused heterocycle options.
References
No sources can be cited from the prompt because no patent bibliographic data (publication/application number, assignee, filing dates, expiration, prosecution history, or related family members) was provided beyond the claim text.
